News

The CDC says that one out of three older adults falls each year, making falls the leading cause of injuries for adults 65 and older. Here’s how some hospitals and programs are addressing the problem.

Report offers some clues regarding healthcare spending disparities

FDA recently approved the first 4-strain, cell culture-derived, inactivated seasonal flu vaccine available in the United States. Flucelvax Quadrivalent influenza vaccine (Seqirus) helps protect against the 2 influenza A viruses and two B viruses recommended by the World Health Organization (WHO) and the FDA for the current influenza season.

In a major new entry in the diabetes market, FDA just approved linagliptin and metformin hydrochloride extended-release tablets (Jentadueto XR, Boehringer Ingelheim and Eli Lilly and Company) to treat type 2 diabetes.

A discussion with Thomas H. Lee, MD, chief medical officer, Press Ganey

Despite their proliferation, at-risk pharma contracts are still little more than value-based window dressing. Here are four critical components of contracts that can actually move the value meter in the right direction.

Industry experts are using their proprietary data/analysis to help structure contracts between pharmaceutical companies and plans.

Novo Nordisk’s new diabetes drug production facility in Clayton, N.C., will ensure production capacity for these drugs in the United States for the decade ahead.

Drug shortages take a toll, especially on emergency department patients.

Preventing drug shortages requires a “swat team” mentality by all, including FDA, manufacturers, group purchasing organizations (GPOs), and health systems. Here’s what healthcare providers should do about the issue.

Preventing hospital readmissions must be top of mind for payers and providers, says Jill Duncan, RN, executive director at the Institute for Healthcare Improvement, where she leads the Joint Replacement Learning Community.

Successful healthcare systems share their strategies for reducing hospital readmissions.

Studies have found that getting diabetes under control early on has immediate benefits. Here’s how providers and patients can more proactively address the disease.

Specific benefits patients with diabetes have experienced due to the ACA, and how those benefits are impacting diabetes costs.

FDA recently granted accelerated approval for atezolizumab (Tecentriq, Genentech), the first drug for bladder cancer that utilizes the body’s immune system. The drug will be available by early June.

At the ASCO 2016 Annual Meeting, an expert from the Moffitt Cancer Center will discuss use of genetics to guide targeted-therapies and immunotherapies.

A value-based cancer care model focuses on better aligning providers with health plans and employers through an IPA.

The ACA risk-adjustment model applies to plans sold in the individual and small group commercial market, including plans sold through exchange marketplaces. Here are four main limitations.

Probuphine implant could be a new option for addicts if obstacles, such as price, don’t get in the way.

FDA has approved lenvatinib (Lenvima, Eisai Inc.) in combination with everolimus for the treatment of advanced renal cell carcinoma.

In alarming news for diabetic patients taking canagliflozin (Invokana, Invokamet) medications, FDA is warning that interim safety results from an ongoing clinical trial found an increase in foot and leg amputations with the drugs.

Although the diabetes pipeline is not large, we continue to have progress in meeting the unmet needs of patients with diabetes.

CMS’ Comprehensive Care for Joint Replacement model will hold hospitals financially responsible for the quality and cost of hip and knee replacements.

Participants in a new CMS payment program will attempt to improve the effectiveness and efficiency of cancer care delivery. Here’s how.

Researchers from Leavitt Partners are using a combination of public and proprietary data to report on some early findings about ACOs.

The industry is awaiting the Supreme Court’s ruling on Universal Health Services v. Escobar. This case concerns the viability of the “implied certification” theory of legal falsity under the False Claims Act.